These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. Lee Y; Bigner DD Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735 [TBL] [Abstract][Full Text] [Related]
4. Cancer vaccines: an update with special focus on ganglioside antigens. Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of local immunoresistance in glioma. Albesiano E; Han JE; Lim M Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963 [TBL] [Abstract][Full Text] [Related]
6. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. Wikstrand CJ; Reist CJ; Archer GE; Zalutsky MR; Bigner DD J Neurovirol; 1998 Apr; 4(2):148-58. PubMed ID: 9584952 [TBL] [Abstract][Full Text] [Related]
7. Antigenic heterogeneity of human brain tumors defined by monoclonal antibodies. Stavrou D; Bise K; Groeneveld J; Stocker U; Kretzschmar HA; Keiditsch E; Mehraein P Anticancer Res; 1989; 9(6):1489-96. PubMed ID: 2697177 [TBL] [Abstract][Full Text] [Related]
8. Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. Wikstrand CJ; Longee DC; McLendon RE; Fuller GN; Friedman HS; Fredman P; Svennerholm L; Bigner DD Cancer Res; 1993 Jan; 53(1):120-6. PubMed ID: 8416736 [TBL] [Abstract][Full Text] [Related]
9. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Sonabend AM; Dana K; Lesniak MS Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318 [TBL] [Abstract][Full Text] [Related]
10. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for human glioma: innovative approaches and recent results. Hussain SF; Heimberger AB Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048 [TBL] [Abstract][Full Text] [Related]
12. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients]. Kubo O; Takakura K Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965 [TBL] [Abstract][Full Text] [Related]
14. Tumor markers of the central nervous system. Birkmayer GD Cancer Detect Prev; 1981; 4(1-4):231-8. PubMed ID: 7349780 [TBL] [Abstract][Full Text] [Related]
15. Tumor immunology: a neurosurgical perspective. II. The immunology of glial neoplasms. Apuzzo ML Bull Los Angeles Neurol Soc; 1976 Oct; 41(4):176-83. PubMed ID: 74264 [TBL] [Abstract][Full Text] [Related]
16. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643 [TBL] [Abstract][Full Text] [Related]
19. Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy. Blasberg RG; Nakagawa H; Bourdon MA; Groothuis DR; Patlak CS; Bigner DD Cancer Res; 1987 Aug; 47(16):4432-43. PubMed ID: 3607773 [TBL] [Abstract][Full Text] [Related]
20. Cell- and peptide-based immunotherapeutic approaches for glioma. Yamanaka R Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]